TNF and cancer: Moreover, there was no difference in the relative cancer risk for any of the individual TNF inhibitor drugs [the risk was 0.64 (95% CI 0.42–0.98) for etanercept, 0.59 (95% CI 0.36–0.97) for infliximab, and 0.49 (95% CI 0.29–0.76) for adalimumab] [59].